Drug-induced liver injury dili - Open Access .click

Results 141 to 150 of about 964 (152)

Some of the next articles are maybe not open access.

Metabolomic approaches in the discovery of potential urinary biomarkers of drug-induced liver injury (DILI)

Critical Reviews in Toxicology, 2017
Drug-induced liver injury (DILI) is a major safety issue during drug development, as well as the most common cause for the withdrawal of drugs from the pharmaceutical market. The identification of DILI biomarkers is a labor-intensive area. Conventional biomarkers are not specific and often only appear at significant levels when liver damage is ...
Araújo, Ana Margarida +4 more
openaire +4 more sources

Diagnosis and Management of Drug-Induced Liver Injury (DILI) in Patients with Pre-Existing Liver Disease

Drug Safety, 2016
The relationship between drugs and pre-existing liver disease is complex, particularly when increased liver tests (LTs) or new symptoms emerge in patients with pre-existing liver disease during drug therapy. This requires two strategies to assess whether these changes are due to drug-induced liver injury (DILI) as a new event or due to flares of the ...
Gaby Danan, Rolf Teschke
openaire +3 more sources

Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies

Journal of Medicinal Chemistry, 2020
Adverse drug reactions (ADRs) are a common cause of attrition in drug discovery and development and drug-induced liver injury (DILI) is a leading cause of preclinical and clinical drug terminations. This perspective outlines many of the known DILI mechanisms and assessment methods used to evaluate and mitigate DILI risk.
openaire +3 more sources

Steatosis as risk factor for drug-induced liver injury (DILI)